Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19511867 | 0.92 | GPR88 (0.41) | CASRNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL28042427 | 0.90 | LTA4H (0.43) | CASRNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL28042230 | 0.90 | SLC7A5 (0.44) | CASRNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL28042424 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LMNASLC7A5 | |
| SCHEMBL28042428 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LMNASLC7A5 | |
| SCHEMBL28106834 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LMNASLC7A5 | |
| SCHEMBL28042430 | 0.89 | SLC7A5 (0.43) | CASRNPC1RAB9ASMN1; SMN2SLC7A5 | |
| SCHEMBL28042426 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LMNASLC7A5 | |
| SCHEMBL28042226 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LMNASLC7A5 | |
| SCHEMBL28042470 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LMNASLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7303739-B2 | Prodrugs for liver specific drug delivery | METABASIS THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050101775-A1 | Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2005-05-12 | — | — | US | disclosed |
| US-6752981-B1 | CYCLIC PHOSPH(ORAMID)ATE PRODRUGS HAVING ALCOHOL, AMINE, ORTHIOL GROUPS ATTACHED TO THE PHOSPHORUS IN THE C3N2P OR C3O2P RING | METABASIS THERAPEUTICS, INC. | 2004-06-22 | — | — | US | disclosed |
| EP-1210354-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | Metabasis Therapeutics, Inc. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001018013-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | METABASIS THERAPEUTICS, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101775-A1 | Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging | PYGL, PHOSPHO1, OAT | CASR 2120/4885NPC1 913/4885RAB9A 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.